pH-responsive albumin-coated biopolymeric nanoparticles with lapatinab for targeted breast cancer therapy
pH-responsive albumin-coated biopolymeric nanoparticles with lapatinab for targeted breast cancer therapy
复制标题
DOI：
10.1016/j.bioadv.2022.213039
复制
发表时间：
2022-07-28
影响因子：
--
通讯作者：
Menaa, Farid
中科院分区：
文献类型：
--
作者：
Iqbal, Haroon;Razzaq, Anam;Menaa, Farid
One can enhance the therapeutic index of anti-cancer drugs using albumin as a tumor homing agent for targeted cancer therapy. Herein, we sought to load lapatinib (LAPA) into small albumin-coated biopolymeric (poly-lactic co-glycolic acid (PLGA)) nanoparticles (APL NPs) by an emulsification method to improve the anti-tumor efficacy of lapatinib. The prepared APL NPs exhibited a small spherical core with an average diameter of 120.5 +/- 10.2 nm with a narrow particle size distribution, high drug loading capacity (LC of 9.65 +/- 1.53 %), good entrapment efficiency (EE of 75.55 +/- 3.25 %), enhanced colloidal stability and a pH-responsive controlled drug release profile. Their cell-uptake and cancer cell growth inhibition were significantly higher compared to free LAPA and uncoated PLGA-LAPA (UPL) NPs, most likely because aggressive breast tumor cells over-express albumin receptors and utilize albumin as nutrient source for their growth. In addition, APL NPs possessed enhanced tumor accumulation and prolonged blood residence time compared to free LAPA and UPL NPs, allowing for potent tumor growth inhibition while exhibiting excellent biosafety. In short, the current study exploited a new and simple strategy to concurrently improve the safety and efficacy of LAPA for breast cancer treatment.
